ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

Dades bàsiques

Protocol:
EURDRACT:
NCT:
Centre:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Any inici:
2023
Any de finalització:
ENSAYO CLÍNICO

Documents

  • No hi ha documents

Participants

Grups d'Investigació

Resultats de l'Assaig Clínic


[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.

Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin

Article. 10.1016/j.farma.2024.08.002. 2024

  • Open Access.

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


Alveolar capillary dysplasia with misalignment of the pulmonary veins: A surgical lung biopsy and autopsy in a full-term newborn.

Rodríguez García C; (...); Mancheño Franch N

Article. 10.1016/j.patol.2024.06.005. 2024

  • Open Access.

BCAS1 defines a heterogeneous cell population in diffuse gliomas.

Morales-Gallel, Raquel; (...); Garcia-Verdugo, Jose Manuel

Article. 10.18632/oncotarget.28553. 2024

  • Open Access.

Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.

Pérez-Alenda S; (...); Núñez-Cortés R

Article. 10.1111/hae.14988. 2024

  • Open Access.

Beyond IDH1 R132H mutation-Clinicopathological characteristics of non-canonical IDH mutant gliomas

Martinez-Saez, E.; (...); Toldos-Gonzalez, O.

Meeting Abstract. 2023


Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.

Herranz R; (...); Medina P

Article. 10.3389/fimmu.2023.1171065. 2023

  • Open Access.

Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


Deep learning automatic semantic segmentation of glioblastoma multiforme regions on multimodal magnetic resonance images.

Beser-Robles, Maria; (...); Marti-Bonmati, Luis

Article. 10.1007/s11548-024-03205-z. 2024


Delving into the clinical impact of NETs in pediatric cancer.

Benavent N; (...); Medina P

Article. 10.1038/s41390-024-03437-4. 2024


Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.

Juan-Ribelles A; (...); Fernández-Teijeiro A

Article. 10.1007/s12094-024-03445-0. 2024

  • Open Access.

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization.

Giner Moreno E; (...); Ramos Soler D

Article. 10.3791/65635. 2023


Extra-Skeletal Osteosarcoma of the Prostate After Treated Prostatic Acinar Adenocarcinoma: A Case Report and Review of the Literature.

García CR; (...); Segura FG

Article. 10.1177/10668969241283735. 2024


Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

  • Open Access.

Normal development of cerebellar vermis in midgestation-A roadmap for pathological diagnosis

Ferrer-Lozano, J.; (...); Llorens-Salvador, R.

Meeting Abstract. 2023


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism.

Cosenza-Contreras, Miguel; (...); Schilling, Oliver

Article. 10.1093/neuonc/noad208. 2023


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Uncovering a novel population of proliferative cells defined by the expression of BCAS1 in glioblastoma

Morales-Gallel, R.; (...); Garcia-Verdugo, J. M.

Meeting Abstract. 2023


Compartir el projecte